Search Bar & Filters
Found 447 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the digital application Deneo Kid, developed in France with input from adolescents, families, rehabilitation providers, and researchers, to see if it can improve the coordination and quality of rehabilitation care for children and young people with neuromotor disabilities. The study focuses on whether the app is easy to use, acceptable, and whether it promotes more integrated, family-centered, and coordinated care, while also considering its impact on communication, relationships, and time and costs related to care coordination. The study involves 20 children and young people aged 2 to 25 years with neuromotor impairments, their parents or legal guardians, and at least two rehabilitation professionals per child. Participants will use the Deneo Kid app for three months to share information, track care goals, and communicate with their care team. The apps use, quality, and impact on care will be evaluated through surveys completed before and after the trial period. Interviews and focus groups will also gather users experiences. Throughout the study, researchers will observe app usage and collect data on usability, acceptability, integrated care, family-centered care, communication, social factors affecting adoption, and care coordination costs and time. Participants will complete questionnaires and take part in interviews or focus groups. The study lasts 12 months including enrollment, with each participant using the app for three months. The goal is to provide information that can guide future larger studies on improving pediatric rehabilitation care through digital tools.
Actively Recruiting
Researchers are exploring the potential use of the imaging agent 68Ga Ga-FAPI in PETCT scans for diagnosing and monitoring various chronic inflammatory and fibrotic diseases. This pilot study focuses on 13 different clinical conditions such as rheumatoid arthritis, liver fibrosis, and systemic lupus to assess whether this new radiotracer can improve disease evaluation compared to current methods. The study aims to gather initial data to guide further development and possible routine use of this imaging technique in these diseases. Participants receive a 68Ga Ga-FAPI PETCT scan in addition to their usual medical care. The imaging is performed either once at baseline or longitudinally at baseline and again at 3 and 6 months if their treatment is intensified at inclusion. This approach allows researchers to observe how the radiotracer behaves in different diseases and over time, helping to refine its clinical application. During the study, participants undergo PETCT scans to measure the intensity of the PET uptake and correlate these findings with pathology evaluations, biomarkers, functional parameters, and imaging characteristics at baseline, 3 months, and 6 months. This detailed assessment helps to understand the diagnostic value of 68Ga Ga-FAPI in chronic inflammatory and fibrotic conditions. The study runs until October 2028 and is conducted at a single center, with participants followed through these imaging and clinical evaluations.
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating GNT0004, a gene therapy using a recombinant adeno-associated viral vector designed to deliver a shortened but functional dystrophin gene to treat Duchenne muscular dystrophy DMD in boys. DMD is caused by mutations in the dystrophin gene, leading to muscle damage from lack of this key protein. This therapy aims to slow disease progression by producing dystrophin in heart and skeletal muscles. The study has three parts. Part 1 involved testing two doses of GNT0004 in five boys to determine the best dose with acceptable safety. Part 2 is a randomized, blinded phase lasting 18 months where participants receive either GNT0004 or a placebo after 18 months, those on placebo switch to GNT0004 and vice versa. Part 3 is a long-term follow-up lasting up to five years to monitor safety and treatment effects in all participants who received GNT0004. Participants undergo assessments including muscle biopsies, blood tests, MRI scans, and functional tests like the North Star Ambulatory Assessment, performed at various times throughout the study. Researchers monitor safety by tracking adverse events and immune responses. Long-term follow-up includes measuring muscle function and respiratory capacity over five years. The study involves ambulant boys aged 6 to 10 years with confirmed DMD who meet specific health criteria.
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
Researchers are conducting a prospective, multicenter cohort study to follow children with idiopathic nephrotic syndrome INS, a rare kidney disease. The study aims to collect data on pediatric patients treated by pediatric nephrologists in France and its overseas territories to better understand the diseases characteristics and support future clinical trials. The study involves regularly recording medical, biological, psychological, and social data through routine clinical follow-ups, hospitalizations, and consultations. Additionally, annual telephone interviews will be conducted for patients in remission. Quality of life, treatment adherence, and treatment impact questionnaires will also be collected. A biobank is established to collect blood, urine, hair, and nail samples at the disease onset before immunosuppressive treatment begins. Participants will be followed from disease onset until age 18 or transfer to adult nephrology care. Data is collected via a secure website, medically validated and entered by clinical research staff. The main outcome is the number of cases included and their characteristics over two years. Participation involves routine care visits, interviews, and questionnaires, with continued monitoring planned through the study period ending in 2048.
Actively Recruiting
Researchers are evaluating a drug called STP938 to treat adults with high risk essential thrombocythaemia ET who do not respond well or cannot tolerate hydroxycarbamide therapy. The study aims to find out if STP938 can control platelet counts effectively and safely in these patients. This phase 2 trial involves individuals who need treatment to lower platelet levels and have already tried hydroxycarbamide without success or due to side effects. Participants will take STP938 capsules daily in 28-day cycles for about 12 months, with the possibility to continue longer if the drug is effective and well tolerated. During the study, participants will have about 26 clinic visits, mostly twice per cycle, for checkups and tests. After treatment, there will be safety follow-up visits to monitor any adverse effects. Procedures include physical exams, ECGs, blood and urine tests, CTMRI scans, bone marrow biopsies, drug level tests, and gene testing. Participants will visit the clinic weekly for the first month, then every two weeks for ongoing monitoring. They will complete monthly symptom questionnaires to help track their condition. Researchers will measure clinical effectiveness and safety throughout the study, including how well STP938 controls platelet counts and its impact on disease-related complications. The total participation time is approximately one year, including treatment and follow-up periods.
1-10 of 447
1